INNOVADERM CRO IS NOW INDERO.

Rheumatology Trial Readiness Checklist

Rheumatology trials are among the most complex in clinical research. Is your CRO prepared? To help you find out, we’ve compiled a checklist of the questions you should ask to uncover hidden gaps that could put your trial at risk.

Key factors covered in this resource include:
  • Scientific and medical expertise specific to rheumatology, beyond general inflammatory disease experience
  • Outcome assessment and data integrity to ensure reliability, with real-time oversight and bias control
  • Proactive risk management, adapted to the complexities of rheumatology trials
  • Operational and scientific infrastructure to execute your protocol successfully

Download your copy today.

One-Pager Form

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.